ESR1 and esophageal cancer: Together, observations from this study and others strongly suggest the therapeutic potential of agents such as fatostatin (this study) and 4-hydroxytamoxifen [51], which can both target estrogen receptors and disrupt lipid metabolism for the treatment of esophageal cancer.